Drug Profile
Fenofibrate/pravastatin - Laboratoires S.M.B
Alternative Names: Duochol; PravaFen; Pravafenix; Pravastatin/fenofibrateLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Galephar Pharmaceutical Research; SMB
- Developer Shionogi Pharma; SMB
- Class Antihyperlipidaemics; Butyric acids; Naphthalenes; Propionates
- Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperlipidaemia
Most Recent Events
- 01 Jan 2018 Yooyoung Pharmaceutical completes the phase III PRADA trial for Hyperlipidaemia in South Korea (PO) (NCT02166593)
- 07 Apr 2015 No recent reports of development identified - Preregistration for Hyperlipidaemia in USA (PO)
- 01 May 2014 Yooyoung Pharmaceutical initiates enrolment in a phase III trial for Hyperlipidaemia in South Korea (PO) (NCT02166593)